MiNK Therapeutics, Inc. INKT
Set alert
As of Nov 2, 2:45 PM ET
- YTD
- -1.61%
- 1 year
- -21.87%
- Open
- 10.41
- Prev close
- 10.53
- Mkt cap
- 55.98M
- Vol
- 10.38K
- Avg vol
- 14.27K
- EPS
- -2.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.41
- High
- 11.48
- Forward P/E
- -1.17
- Beta
- 0.05
- Short ratio
- 1.10
- Inst. own
- 2.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 0.68846
- 200-d avg
- 0.846145
- 1y target
- 6.50
News
-
1 week ago benzinga.com
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
1 month ago globenewswire.com
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell…
1 month ago globenewswire.com
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature
2 months ago seekingalpha.com
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
MiNK Therapeutics Q2 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and…
2 months ago benzinga.com
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
-
2 months ago benzinga.com
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of…
2 months ago globenewswire.com
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT)…
2 months ago globenewswire.com
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies…
3 months ago zacks.com
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago globenewswire.com
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)…
5 months ago globenewswire.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for…
5 months ago globenewswire.com
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell…
5 months ago seekingalpha.com
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 months ago globenewswire.com
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase…
5 months ago globenewswire.com
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and…
5 months ago globenewswire.com
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic…
5 months ago globenewswire.com
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to…
7 months ago defenseworld.net
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold” by Brokerages
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One…
7 months ago globenewswire.com
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell…
7 months ago globenewswire.com
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell…
-
7 months ago benzinga.com
Earnings Scheduled For March 31, 2026
Earnings Scheduled For March 31, 2026
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago benzinga.com
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
10 months ago benzinga.com
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
Earnings Scheduled For November 14, 2025
Earnings Scheduled For November 14, 2025
-
1 year ago benzinga.com
Earnings Scheduled For August 14, 2025
Earnings Scheduled For August 14, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
1 year ago benzinga.com
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings